Search

Your search keyword '"Froelich, L."' showing total 144 results
Start Over Author "Froelich, L." Publication Type Academic Journals
144 results on '"Froelich, L."'

1. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Author

Vellas, B., Reynish, E., Ousset, P.J., Andrieu, S., Burns, A., Pasquier, F., Frisoni, G., Salmon, E., Michel, J.P., Zekry, D.S., Boada, M., Dartigues, J.F., Olde-Rikkert, M.G.M., Rigaud, A.S., Winblad, B., Malick, A., Sinclair, A., Frölich, L., Scheltens, P., Ribera, C., Touchon, J., Robert, P., Salva, A., Waldemar, G., Bullock, R., Tsolaki, M., Rodriguez, G., Spiru, L., Jones, R.W., Stiens, G., Stoppe, G., Eriksdotter Jönhagen, M., Cherubini, A., Lage, P.M., Gomez-Isla, T., Camus, V., Agüera-Morales, E., Lopez, F., Savy, S., Cantet, C., Coley, N., Vermunt, Lisa, Sikkes, Sietske A.M., van den Hout, Ardo, Handels, Ron, Bos, Isabelle, van der Flier, Wiesje M., Kern, Silke, Ousset, Pierre-Jean, Maruff, Paul, Skoog, Ingmar, Verhey, Frans R.J., Freund-Levi, Yvonne, Tsolaki, Magda, Wallin, Åsa K., Olde Rikkert, Marcel, Soininen, Hilkka, Spiru, Luisa, Zetterberg, Henrik, Blennow, Kaj, Scheltens, Philip, Muniz-Terrera, Graciela, and Visser, Pieter Jelle

Published
2019
Full Text
View/download PDF

5. The primary care physician and Alzheimer's disease: An international position paper

Author

Villars, H., Oustric, S., Andrieu, S., Baeyens, J.P., Bernabei, R., Brodaty, H., Brummel-Smith, K., Celafu, C., Chappell, N., Fitten, J., Frisoni, G., Froelich, L., Guerin, O., Gold, G., Holmerova, I., Iliffe, S., Lukas, A., Melis, R., Morley, J.E., Nies, H., Nourhashemi, F., Petermans, J., Ribera Casado, J., Rubenstein, L., Salva, A., Sieber, C., Sinclair, A., Schindler, R., Stephan, E., Wong, R.Y., and Vellas, B.

Published
2010
Full Text
View/download PDF

7. Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing

Author

Lewczuk, P., Kornhuber, J., Vanmechelen, E., Peters, O., Heuser, I., Maier, W., Jessen, F., Bürger, K., Hampel, H., Frölich, L., Henn, F., Falkai, P., Rüther, E., Jahn, H., Luckhaus, Ch., Perneczky, R., Schmidtke, K., Schröder, J., Kessler, H., Pantel, J., Gertz, H.-J., Vanderstichele, H., de Meyer, G., Shapiro, F., Wolf, S., Bibl, M., and Wiltfang, J.

Published
2010
Full Text
View/download PDF

9. A Longitudinal Study of Transitions Between Informal and Formal Care in Alzheimer Disease Using Multistate Models in the European ICTUS Cohort

Author

Vellas, B., Reynish, E., Ousset, P.J., Andrieu, S., Burns, A., Pasquier, F., Frisoni, G., Salmon, E., Michel, J.P., Zekry, D.S., Boada, M., Dartigues, J.F., Olde-Rikkert, M.G.M., Rigaud, A.S., Winblad, B., Malick, A., Sinclair, A., Frölich, L., Scheltens, P., Ribera, C., Touchon, J., Robert, P., Salva, A., Waldmar, G., Bullock, R., Costa-Tsolaki, M., Rodriguez, G., Spiru, L., Jones, R.W., Stiens, G., Stoppe, G., Eriksdotter Jönhagen, M., Cherubini, A., Lage, P.M., Gomez-Isla, T., Camus, V., Agüera-Morales, E., Lopez, F., Savy, S., Cantet, C., Coley, N., Coley, Nicola, Gallini, Adeline, Garès, Valérie, Gardette, Virginie, and Andrieu, Sandrine

Published
2015
Full Text
View/download PDF

12. Abstracts Second Congress of the European Society for Clinical Neuropharmacology: Würzburg, November 9–11, 1995

Author

Agid, Y., Arendt, T., Gärtner, U., Holzer, M., Fruth, P., Brückner, M. K., Arzberger, T., Weindl, A., Baas, H., Demisch, L., Harder, S., Bürklin, F., Fischer, P. A., Bagli, M., Rao, M. L., Sobanski, T., Laux, G., Barbier, P., Fumagalli, F., Donati, E., Maggio, R., Racagni, G., Corsini, G. U., Riva, M., Berger, J., Löschl, B., Bernheimer, H., Lugowska, A., Tylki-Szymanska, A., Gieselmann, V., Molzer, B., Faé, I., Bernocchi, G., Scherini, E., Necchi, D., Bigl, M., Bleyl, D., Bigl, V., Eschrich, K., Block, F., Schwarz, M., Blum-Degen, D., Müller, Th., Kuhn, W., Gerlach, M., Przuntek, H., Riederer, R., Bonuccelli, U., Ceravolo, R., Nuti, A., D'Avino, C., Placidi, G., Perugi, G., Cassano, G. B., Del Dotto, P., Piccini, P., Colzi, A., Muratorio, A., Braak, H., Braak, E., Yilmazer, D. M., de Vos, R. A. I., Jansen, E. N. H., Bringmann, G., Clement, H. W., Grote, C., Rausch, F., Reichmann, H., Riederer, P., Sontag, K. -H., Wesemann, W., God, R., Feineis, D., Brückner, R., Protzen, J. -A., Fähr, S., Rausch, W. -D., Brunt, E. R. P., Pruim, J., Willemsen, A. J., van Weerden, T. W., Bryan-Lluka, L. J., Bönisch, H., Büttner, Th., Kühn, W., McMonagle, U., Calza, L., Pozza, M., Coraddu, F., Farci, G., Carlsson, A., Napolitano, A., Salvetti, S., Dell'Agnello, G., Renna, M., Conquet, F., Bashir, Z., Daniel, H., Ferraguti, F., Collingridge, G., Crépel, F., Coos Verhoef, J., Merkus, F. W. H. M., Junginger, H. E., Cruz-Sánchez, F. F., Kutschka, T., Beeg, M., Deuschle, M., Weber, B., Körner, A., Standhardt, H., Lammers, C. -H., Motzek-Noé, T., Heuser, I., Earl, C. D., Reum, T., Sautter, J., Xie, J. -X, Kupsch, A., Oertel, W. H., Morgenstern, R., Emilien, G. M., Maloteaux, J. M., Seghers, A., Charles, G., Erdmann, R., Högemann, D., Fichter, N., Lücking, C. H., Landwehrmeyer, G. B., Winter, T., Feuerstein, T. J., Fitzgeral, D., Anderson, M. C., Lawlor, B., Tipton, K. F., Frackowiak, R. S. J., Freo, U., Dam, M., Pizzolato, G., Merico, A., Ori, C., Sale, E., Battistin, L., Fritze, J., Froelich, L., Goetz, M., Gsell, W., Jellinger, K., Beckmann, H., Fünfgeld, E. W., Glinka, Y., Youdim, M. B. H., Götz, M. E., Breithaupt, W., Burger, R., Streifler, M., Simanyi, M., Müller, F., Danielczyk, W., Hirning, T., Sohlbach, M., Nafc, R., Sternadl, H., Winter, M., Nöth, U., Heim, C., Hartmann, J., Künig, G., Niedermeyer, B., Berger, W., Deckert, J., Abel, F., Heinsen, H., Senitz, D., Mayr, J., Ransmayr, G., Hartung, H. -P., Heils, A., Teufel, A., Petri, S., Seemann, M., Bengel, D., Degen, H. J., Lesch, K. P., Sontag, T., Heinen, F., Korinthenberg, R., Heiss, W. -D., Rüb, U., Gangus, B., Jungkunz, G., Bauer, M., Ulmar, G., Böcker, F., Schüler, M., Bethke, B., Lockemann, U., Hermans, E., Vanhoorde, P., Hesse, S., Hüll, M., Fiebich, B., Lieb, K., Strauss, S., Berger, M., Volk, B., Bauer, J., Iversen, L. L., Janetzky, B., Hauck, S., Jeanjean, A. P., Laterre, E. C., Bancher, C., Jost, W. H., Kalus, P., Kanner, B., Khrapova, E. V., Brusov, O. S., Knauber, J., Müller, W. E., Korczyn, A. D., Kornhuber, J., Parsons, C. G., Hartmann, S., Retz, W., Kamolz, S., Thome, J., Koutsilieri, E., Chen, T. -S., Kreutzberg, G. W., Krieglstein, J., Winkel, R., Danielcyk, S., Gerstner, A., Mattern, C., Häcker, R., Labunsky, D., Zhirnova, I., Komelkova, L., Popova, L., Avdiunina, I., Lakke, J. P. W. F., Lange, K. W., Steup, A., Tucha, O., Naumann, M., Lassmann, H., Leszek, J., Gasiorowski, K., Inglot, D., Lohse, M. J., Löschmann, P. -A., Eblen, F., Wüllner, U., Klockgether, T., Dichgans, J., Macrae, I. M., Mimmack, M. L., Emson, P., Norta, M., Borchert, H. -H., Medori, R., Chan, W. W., Heinemann, T., Melzacka, M., Kolasiewicz, W., Sieklucka, M., Jaros, T., Mesec, A., Šega, S., Kiauta, T., Moser, A., Vieregge, P., Siebecker, F., Münch, G., Schinzel, R., Michaelis, J., Cunningham, A., Da Prada, M., Borroni, E., Zürcher, G., Reiners, K., Neveu, P. J., Nitsch, R. M., Pavese, N., Lucetti, C., Rossi, G., Offen, D., Ziv, I., Stein, R., Barzilai, A., Hochman, A., Melamed, E., Ozawa, H., Hashimoto, E., Saito, T., Ymamoto, M., Takahata, N., Frölich, L., Paulus, W., Hermsteiner, E., Haug, B., Bandelow, B., Peckys, D., Gleichauf, O., Jackisch, R., Landwehrmeyer, B., Bloß, H. G., Plaschke, K., Müller, D., Hoyer, S., Avdyuna, L. A., Putzke, J., Spanagel, R., Tolle, T. R., Zieglgänsberger, W., Rabey, J. -M., Orlov, E., von Raison, F., Lehmann, K., Havemann-Reinecke, U., Butà, M., Federspiel, S., Maier, H., Abdel-mohsen, M., Abdel-moneim, M., Reynolds, G. P., Sardar, A. M., Eggett, C. J., Rosario, P., de la Morena, E., José Barro, M., Rossini, P. M., Roth, J., Růžička, E., Svobodová, I., Mečíř, P., Jech, R., Remeš, F., Kleinschroth, A., Schliebs, R., Roßner, S., Heider, M., Schubert, H., König, P., Schuttes, H., HaveIec, L., Schwartz, J. -C., Sendtner, M., Smith, A., Li, M., Griesbeck, O., Parsadanian, A., Holtmann, B., Carroll, P., Toyka, K. V., Thoenen, H., Sharkawy, A. A., Ibrahim, T. A., Pulkowski, U., Siesjö, B. K., Klessaschek, M., Sopper, S., Demuth, M., Dörries, R., Hemm, S., Stahl-Hennig, C., Brinkmann, R., ter Meulen, V., Sperk, G., Schwarzer, C., Stern, G., Storm, G., Strein, I., Struck, M., Stürenburg, H. J., Kunze, K., Svadovsky, A. I., Morgunov, K. V., Peresedov, V. V., Moshkin, A. V., Teherani, D. K., Baumer, A., Rösier, M., Rösler, M., Wiesbeck, G. A., Wodarz, N., Boning, J., Timerbaeva, S. L., Alekseeva, N. S., Toso, A., Barletta, D., Tuulik, V., Lossmann, E., Raja, A., Meister, A., Uitti, R. J., Rajput, A. H., Ahlskog, J. E., Offord, K. P., Schroeder, D. R., O'Brien, P. C., Vaglini, F., Fascetti, F., Pardini, C., Mancino, L., Velbinger, K., Hartmann, H., Eckert, A., Grüter, S., Behrens, S., Niemann, J., Guschelbauer, B., Lauk, M., Wissel, J., Poewe, W., Wurthman, C., Janzen, E. N. H., Goping, G., Adegemo, O. M., Gemma, A., Kuijpers, J., Pollard, H. B., Zielke, B., Ziemann, U., and Bruns, D.

Published
1995
Full Text
View/download PDF

22. Multi-center comparison of medial temporal atrophy in patients with Alzheimer's disease -- data from the ICTUS study.

Author

Galluzzi S, Talassi E, Belussi M, Scheltens P, van de Pol L, Nobili F, Rodriguez G, Froelich L, Damian M, Martinez-Lage P, Gomez-Isla T, Reynish E, Ousset PJ, Vellas B, and Frisoni GB

Abstract

Objective: To study multi-center variability of medial temporal lobe atrophy (MTA) in patients with Alzheimer's disease (AD) recruited in a European observational study of AD. Methods: 117 mild to moderate AD patients from 5 European centers (Amsterdam, The Netherlands; Brescia and Genova, Italy; Mannheim, Germany; Pamplona, Spain) had magnetic resonance imaging scans performed as part of the routine diagnostic examination. MTA was assessed with the visual Scheltens scale. Results: AD patients from Brescia, Genova, Pamplona, and Mannheim had a mean 32% prevalence of no or borderline MTA vs. 62% of patients from Amsterdam (p = 0.002 for the difference between Amsterdam and all the other centers). The peculiar distribution of MTA in the Amsterdam patients may be attributable to younger age (70.7 ± 8.4 vs. 75.3 ± 6.8 years, p = 0.002), milder dementia severity (score 0.5 on the clinical dementia rating scale: 52 vs. 23%, p = 0.003), and less frequent depression (14 vs. 49%, p < 0.0005 in Amsterdam vs. all the other centers, respectively). Conclusion: Patients with probable AD recruited in different centers of Europe generally have similar MTA distribution, even if peculiar demographic and clinical findings might explain occasional differences. These results have implications for clinical trials in AD with biological markers as outcome measures. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

23. Donepezil for Alzheimer's Disease in Clinical Practice -- The DONALD Study.

Author

Froelich, L., Gertz, H.-J., Heun, R., Heuser, I., Jendroska, K., Kornhuber, J., Kurz, A., Mueller-Thomsen, T., Ries, F., Waechtler, C., Metz, M., and Goebel, C.

Subjects
*CLINICAL trials, *ALZHEIMER'S disease treatment, *PATIENTS, *THERAPEUTICS
Abstract

This multicenter open-label clinical trial was designed to investigate the safety and efficacy of donepezil, a selective acetylcholinesterase inhibitor, in the treatment of Alzheimer's disease (AD) in routine clinical practice in Germany. A total of 237 patients with mild-to-moderate AD were treated with donepezil for 24 weeks, 186 completed the study according to the protocol. In the completer group, mean MMSE score for efficacy showed an improvement from baseline of +1.6 points at week 12 (95% CI +1.1 to +2.1) and of +1.1 points at week 24 (95% CI +0.5 to +1.7). In more than 80% of the patients, global tolerability was rated to be very good or good. There were only insignificant effects on ECG parameters. This study confirms the results obtained in previous double-blind trials, which showed that donepezil is effective and well tolerated in patients with mild-to-moderately severe AD. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

25. Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist.

Author

MARDER, P., SPAETHE, S. M., FROELICH, L. L., CERIMELE, B. J., PETERSEN, B. H., TANNER, T., and LUCAS, R. A.

Abstract

1The effects of orally administered LY293111 on ex vivo neutrophil Mac-1 upregulation were determined in a total of 24 healthy male subjects within three study periods. 2In the first period, eight volunteers received 60 mg LY293111 or placebo three times daily in 22 total doses over 8 days followed by a 1 week follow-up. The average ex vivo Mac-1 response of the LY293111 group was 56% of the pre-dose control (95% confidence interval (CI) 44.3 to 67.9%; P<0.01). The inhibitory effect was maximum at the end of dosing and had disappeared by day 14. 3In the second period, eight subjects received 120 mg LY293111 or placebo three times daily in 22 total doses over 8 days followed by a 1 week follow-up. The average response of the LY293111 group was 70% of the pre-dose control (95% CI 59.7 to 81.0%; P<0.01). The inhibitory effect was maximum the day following the initial dose and continued throughout the dosing period. 4In the third period, eight subjects received 200 mg LY293111 or placebo twice daily in 15 total doses over 8 days followed by a 1 week follow-up. Mac-1 upregulation was 64% of pre-dose levels (95% CI 53.8 to 75.1%; P<0.01) over the course of the study period. The inhibition had disappeared 2 days following the final dose. Alternate neutrophil stimulation by fMLP was not inhibited. 5No statistically significant inhibition was observed for placebo-treated subjects. 6No statistically significant differences were apparent between the active dose regimens. 7The results indicate that orally administered LY293111 is pharmacologically active in humans. Results from this study may be useful in determining dose selection for efficacy trials. [ABSTRACT FROM AUTHOR]

Published
1996
Full Text
View/download PDF

26. Les trains-hôpitaux de la Croix-Rouge.

Author

Froelich, L.

Abstract

L'Italie, longtemps en retard au point de vue de l'organisation du transport des blessés par chemins de fer, a prouvé, dans ces dernières années, qu'elle comprenait l'importance capitale de cet élément du service de santé en campagne.Après diverses missions à l'étranger (Bellina, Cortese, etc.) où les systèmes les plus variés firent l'objet d'études approfondies, après de nombreux travaux, tels que ceux de Baroffio, Tosi, Gottardi, Di Fede, Randone, un règlement spécial sur la matière fut élaboré par le ministère de la guerre Bertole-Viale, et enfin agréé par S. M. le roi Humbert, en date du 24 novembre 1889. [ABSTRACT FROM PUBLISHER]

Published
1892
Full Text
View/download PDF

40. ChemInform Abstract: Synthetic and Structure-Activity Studies on Acid-Substituted 2- Arylphenols: Discovery of 2-(2-Propyl-3-(3-(2-ethyl-4-(4-fluorophenyl)- 5-hydroxyphenoxy)propoxy)phenoxy)benzoic Acid, a High-Affinity Leukotriene B4 Receptor Antagonist.

Author

SAWYER, J. S., BACH, N. J., BAKER, S. R., BALDWIN, R. F., BORROMEO, P. S., COCKERHAM, S. L., FLEISCH, J. H., FLOREANCIG, P., FROELICH, L. L., JACKSON, W. T., MARDER, P., PALKOWITZ, J. A., ROMAN, C. R., SAUSSY, D. L. JUN., SCHMITTLING, E. A., SILBAUGH, S. A., SPAETHE, S. M., STENGEL, P. W., and SOFIA, M. J.

Published
1996
Full Text
View/download PDF

42. Lecanemab in Early Alzheimer's Disease.

Author

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., and Iwatsubo, T.

Subjects
*ALZHEIMER'S disease, *PATHOGENESIS, *CLINICAL trials, *CEREBROSPINAL fluid, *MILD cognitive impairment, *LECANEMAB
Abstract

Background: The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer's disease.Methods: We conducted an 18-month, multicenter, double-blind, phase 3 trial involving persons 50 to 90 years of age with early Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's disease) with evidence of amyloid on positron-emission tomography (PET) or by cerebrospinal fluid testing. Participants were randomly assigned in a 1:1 ratio to receive intravenous lecanemab (10 mg per kilogram of body weight every 2 weeks) or placebo. The primary end point was the change from baseline at 18 months in the score on the Clinical Dementia Rating-Sum of Boxes (CDR-SB; range, 0 to 18, with higher scores indicating greater impairment). Key secondary end points were the change in amyloid burden on PET, the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90; higher scores indicate greater impairment), the Alzheimer's Disease Composite Score (ADCOMS; range, 0 to 1.97; higher scores indicate greater impairment), and the score on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL; range, 0 to 53; lower scores indicate greater impairment).Results: A total of 1795 participants were enrolled, with 898 assigned to receive lecanemab and 897 to receive placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, -0.45; 95% confidence interval [CI], -0.67 to -0.23; P<0.001). In a substudy involving 698 participants, there were greater reductions in brain amyloid burden with lecanemab than with placebo (difference, -59.1 centiloids; 95% CI, -62.6 to -55.6). Other mean differences between the two groups in the change from baseline favoring lecanemab were as follows: for the ADAS-cog14 score, -1.44 (95% CI, -2.27 to -0.61; P<0.001); for the ADCOMS, -0.050 (95% CI, -0.074 to -0.027; P<0.001); and for the ADCS-MCI-ADL score, 2.0 (95% CI, 1.2 to 2.8; P<0.001). Lecanemab resulted in infusion-related reactions in 26.4% of the participants and amyloid-related imaging abnormalities with edema or effusions in 12.6%.Conclusions: Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer's disease. (Funded by Eisai and Biogen; Clarity AD ClinicalTrials.gov number, NCT03887455.). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results